405 filings
Page 5 of 21
6-K
sgpe05
7 Feb 22
Current report (foreign)
2:40pm
6-K
ctamjo24cjdi02dvr
27 Jan 22
Galapagos appoints Paul Stoffels as Chief Executive Officer
12:00am
6-K
9xs06s se
26 Jan 22
Galapagos creates new subscription right plan
5:30pm
6-K
bhac3h7z2mpukpwdwzh8
19 Jan 22
Jyseleca®▼ (Filgotinib) Licensed for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis In Great Britain
11:37am
6-K
tduawn6 bci2k3
13 Jan 22
Galapagos creates new subscription right plan
4:32pm
6-K
5pbqgqvyn 6ms9n
10 Jan 22
Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
3:12pm
6-K
y8wbppk ldlvn5b2x
6 Dec 21
Current report (foreign)
6:00am
6-K
ig789uu4lrclfp
29 Nov 21
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
6:00am
6-K
lieavzd7sa70aq9yb
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am
6-K
uqbhk
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
S-8
po0 nd07ygwfpj7xe
26 Oct 21
Registration of securities for employees
4:07pm
6-K
fkfz4skw1x3t y6
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
6-K
znn20i
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
hurlb eqi
21 Sep 21
Current report (foreign)
12:00am
6-K
j3vc103
20 Sep 21
Current report (foreign)
9:26am
6-K
xdeuiyt 4ld6rk
31 Aug 21
Galapagos announces planned retirement of CEO
3:46pm
6-K
cd5vdbjwyb6m5rti
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
utk 0jvwr
14 Jul 21
Current report (foreign)
5:27pm
6-K
pbnmg3hi
14 Jul 21
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
5:13pm
6-K
kkejrw6k
12 Jul 21
New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress
9:02am